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Abstract 
Type 1 diabetes (T1D) is a non-preventable autoimmune disease where autoreactive T 
cells orchestrate the destruction of insulin-producing pancreatic beta cells. Individuals with T1D 
are committed to a life-long dependency on insulin, which it and T1D associated care is 
expensive, and in many regions around the world is unattainable. Thus, there is an imperative to 
find an accessible and efficient alternative. The seeds of Garcinia kola are commonly used for 
cultural and medicinal purposes in West Africa. Previous studies have shown that Garcinia kola 
seed extract (GKE) has hypoglycemic and anti-inflammatory effects which suit is as a candidate 
for preventing disease development. It was hypothesized that treatment with GKE would prevent 
T1D development through its anti-inflammatory action in an experimental mouse model. Male 
seven-week-old C57BL/6J mice were treated with aqueous or ethanol GKE (100 mg/kg) in their 
drinking water for five weeks and were chemically induced with T1D at eight weeks of age. 
Biweekly body weight and glycemia measurements were performed from nine to 13 weeks of 
age. Mice were euthanized at days 11 and 30 after the initial STZ injection to evaluate GKE’s 
effects on T cells. Treatment with GKE had no effect on glycemia, diabetes incidence or 
prevalence. However, the immunomodulatory activity of GKE displayed a shift to a pro-
inflammatory response, suggesting potential therapeutic benefits for other diseases. This study 
did not confirm the anti-diabetic potential of GKE, however, it did highlight the need for more 
consistent research on herbal compounds. 
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Chapter I: Introduction 
Over the past few decades, diabetes has become a global issue due to the increasing 
incidence, rate of inadequate access to treatment, and morbidity. There have been approximately 
347 million deaths, and diabetes is anticipated to be the seventh leading cause of death 
worldwide by 2030 (Sharma, Petersen, Nazareth, & Coton, 2016). The mortality rate in 2017 
from diabetes and its associated complications was approximately 11% among people aged 20-
79, this is higher than the combined rate of deaths from HIV/AIDS, tuberculosis, and malaria 
(International Diabetes Federation [IDF], 2017).  In 2017, there was a global estimate of 425 
million people with diabetes and is projected to increase to 628 million people by 2045 (IDF, 
2017). At least 90% of these individuals have type 2 diabetes (T2D), and type 1 diabetes (T1D) 
accounts for approximately 5-10%. Historically, T1D has been referred as juvenile-onset 
diabetes, and T2D affects adults, but T2D prevalence in youth has become significantly more 
frequent within the past two decades (D’Adamo & Caprio, 2011). However, T1D is still the most 
common form of diabetes seen in children, and there is an estimated 3-5% global increase in 
incidence annually; in 2015, over 540,000 children had T1D. Less developed countries have 
been experiencing the highest increased rate (IDF, 2015).  
T1D related care, such as glucose monitoring tools, insulin treatment, and hospital visits- 
are very expensive; T1D related care costs the United States approximately $14.4 billion (Tao, 
Pietropaolo, Atkinson, Schatz, & Taylor, 2010). If there were to be a new therapy that would 
potentially eliminate this disease, an approximate $422 billion would be saved by existing T1D 
patients in their lifetime (Tao et al., 2010). An approximate $4,700 is the annual cost of T1D 
related expenses per child, and the bulk of the spending is related to glucose monitoring tools 
and insulin treatment (Bächle et al., 2013).  
12 
 
Type 1 Diabetes  
T1D results with hyperglycemia induced by T lymphocyte (T cell)-mediated autoimmune 
attack of insulin-producing beta-cells within pancreatic islets (Atkinson, 2012). It has been 
proposed that a combination of genetic and environmental factors initiates disease development; 
environmental factors that are significantly associated with T1D development include viral 
infections, exposure to persistent organic pollutants, consumption of cow’s milk, lack of Vitamin 
D, maternal age of childbirth over 35, and child delivery via cesarean section (Ahadi, 
Tabatabaeiyan, & Mozzami, 2011). Although, recently, environmental factors seem to be a far 
greater risk for T1D development (Krzewska & Ben-Skowronek, 2016). Particular alleles of, 
human leukocyte antigen (HLA) class II genes has high association with T1D development. 
HLA class II is located on antigen presenting cells (B lymphocytes, macrophages, and dendritic 
cells) which activate helper T cells (Dean & McEntyre, 2004). An additional theory explaining 
T1D development is molecular mimicry. It is thought that epitopes on viruses, such as the 
Coxsackie B4, are structurally similar to epitopes on beta cells, and can affect T cell maturation 
and activation (Cusick, Libbey, & Fujinami, 2012). 
Clinical symptoms of hyperglycemia include polyuria, polyphagia, polydipsia, and 
weight loss. Poor management of hyperglycemia can lead to more serious health consequences 
including kidney disease, nerve damage, and retinopathy (IDF, 2015). People with T1D are 
dependent on life-long insulin therapy, and continuous glucose monitoring. Insulin therapy can 
be administered via injections or through a pump system (Chamberlain et al., 2017).  
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Immunology of Type 1 Diabetes  
The immune system is divided into two branches- innate and adaptive. The innate branch 
is not specific, but has perfect self and non-self recognition due to the lack of specificity. Cells of 
the innate branch include phagocytes such as macrophages and non-phagocytes including natural 
killer (NK) cells (Turvey & Broide, 2010). The adaptive branch is very specific and elicits a 
more powerful response, problems of self recognition can arise; T cells and B cells are the cells 
of this branch. There are three T cell populations that can be identified by their surface markers 
called clusters of differentiation (CD): T helper (Th),  by CD4 marker, T cytotoxic (Tc), by CD8 
marker, and T regulatory (Treg) cells by  CD4 and CD25 markers. Th cells can be further divided in 
three subtypes: Th1, Th2, and Th17 (Bonilla & Oettgen, 2010). In a healthy immune system, 
there is a balance between Th1, Tc, and Th17 cells which release pro-inflammatory cytokines, 
and Th2 and Treg cells which release anti-inflammatory cytokines. During T1D development, it 
is thought that pathogenic T-cells including Th1, Th17 and Tc, potentiate beta cell destruction by 
the secretion of interferon-γ (IFNγ), interleukin 17a (IL-17a), and tumor necrosis factor-α 
(TNFα). In contrast, Th2 and Treg, which release interleukin 4 (IL-4) and interleukin 10 (IL-10) 
are believed to be protective cells, trying to prevent the destruction initiated by the pathogenic T 
cells (Wagner, 2011). The destruction of beta cells begins with the activation of Th cells by 
antigen presenting cells, followed by the differentiation into Th1 cells. Th1 cells then recruit Tc 
and macrophages by releasing cytokines, IL-2 and IFNγ, to propagate beta cell destruction 
(Yoon & Jun, 2005). Hallmarks of T1D include insulitis and chronic hyperglycemia; insulitis 
refers to the islet inflammation, characterized by accumulation of T cells and macrophages.  
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Experimental Mouse Models of Type 1 Diabetes  
To understand the mechanism of T1D development, experimental mouse models have 
been used. There are two common models used to study experimental T1D: female NOD/LtJ 
mouse model with spontaneous T1D development, and chemically-induced T1D in male 
C57BL/6J mice. The spontaneous model of T1D development is a model that is most similar to 
how humans develop the disease and is regarded to be the top standard for studying how 
different compounds affect disease development (Shoda et al., 2005). However, this model 
requires a long time, usually about six months to a year (depends on the colony) for mice to 
become diabetic. On average, female NOD/LtJ mice start becoming diabetic from 12 weeks of 
age (Shoda et al., 2005). To ensure T1D development in C57BL/6J mice, multiple low-doses of 
Streptozotocin (STZ) (MLDSTZ) are administered intraperitoneally (Cetkovic-Cvrlje, 
Thinamany, & Bruner, 2017). STZ is an anti-cancer drug for pancreatic cancers due to its beta 
cell specific toxicity. STZ is classified as a glucosamine-nitrosourea compound, one of its 
mechanisms of action is DNA damage which induces poly ADP-ribosylation. Poly ADP-
ribosylation results in the decline of cellular ATP, resulting in the inhibition of insulin synthesis 
(Szkudelski, 2001). Due to its similarities to glucose, STZ is transported to beta cells by the 
glucose transport protein, GLUT-2 (Wang & Gleichmann, 1998). MLDSTZ treatment is believed 
to initiate the release of autoantigens, such as glutamic acid decarboxylase, triggering beta cell 
autoimmunity, and inducing the Th1-dependent inflammatory response (Van Belle, Taylor, & von 
Herrath, 2009). STZ can also be administered in a single high-dose. The single high-dose STZ 
does not trigger beta cell autoimmunity like the MLDSTZ. Instead, beta cells are rapidly 
destroyed, and hyperglycemia is immediate (King, 2012). Another common T1D chemical 
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inducer is alloxan (2,4,5,6-tetraoxypyrimidine; 5,6-dioxyuracil), which is generally injected in a 
single, high-dose, therefore not inducing the autoimmune development of T1D. Alloxan is 
structurally similar to glucose and is transported to beta cells by the GLUT-2 transporter. Beta 
cell destruction is induced by glucokinase inhibition and the generation of reactive oxygen 
species (ROS) (Lenzen, 2008). Alloxan also induces beta cell destruction by the oxidation of 
important thiol groups and disrupting intracellular calcium homeostasis (King, 2012).  
Flavonoids 
 Flavonoids are a ubiquitous secondary metabolite present in plants that are often 
responsible for pigmentation, and also contribute to protection against microbial and 
environmental stressors. They are also common in fruits, vegetables, and herbs, where they are 
often referred as dietary flavonoids (Panche, Diwan, & Chandra, 2016). The structural skeleton 
of a flavonoid consists of 15 carbons with two aromatic rings that are connected together with a 
three-carbon bridge (Figure 1); structural differences within the B and C rings of the flavonoid 
skeleton yield subclasses of flavonoids, including flavanol, flavone, isoflavone, anthocyanidin, 
and flavanone (Del Rio et al., 2013). Flavonoids have been reported to exhibit anti-oxidant and 
anti-inflammatory properties that are influenced by modifications in the skeletal structure 
(Rengasamy et al., 2018). Structural requirements for anti-oxidant activity include an o-
dihydroxy structure in the B ring, the presence of 3-OH and 5-OH groups, and a C2-C3 double 
bond (Rengasamy et al., 2018). 
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Figure 1.  Structure of a flavonoid and the six subtypes (Del Rio et al., 2013). 
Garcinia kola  
Garcinia kola, a member of the Guttiferae family, is a large tree that is dominantly grown 
in Central and West Africa. The seeds (bitter kola), stem and bark act as an intricate staple in 
African culture and medicine, used for treatments of laryngitis, cold, liver disease, fertility 
complications, and hepatitis (Adedara, Awogbindin, Anamelchi, & Farombi, 2015; Iwu, Igboko, 
Okunji, & Tempesta, 1990).  Garcinia kola seed extracts (GKE) contain Kolaviron (KV), a 
biflavonoid mixture consisting of Garcinia biflavonoid (GB)-1, GB-2, kolaflavanone, 
kolaflavone, and binarigenin (Oyenihi, Brooks, & Oguntibeju, 2015). KV has been reported to 
have beneficial effects, such as anti-microbial, anti-oxidative, anti-inflammatory, and 
hypoglycemic (Farombi & Owoeye, 2011).  
Hypoglycemic Potential of Garcinia kola 
 Iwu et al demonstrated hypoglycemic properties of KV, extracted by light petroleum 
ether/acetone/chloroform Soxhlet method, in alloxan-induced T1D rabbits. Significant decreases 
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in fasting glycemia levels were observed in both diabetic and normoglycemic rabbits treated with 
KV (Iwu et al., 1990). Other studies done in Wistar rats, using a single-dose of STZ (50 mg/kg, 
65 mg/kg, and 35 mg/kg) found a significant decrease in fasting glucose levels in both normal 
and diabetic rats treated with KV in a dose of 100 mg/kg (Adaramoye & Adeyemi, 2006; 
Adaramoye, 2012; Ayepola, Brooks, & Oguntibeju, 2014; Ayepola, Cheogou, Brooks & 
Oguntibeju, 2013). Interestingly, it has been shown that glycemia levels were significantly 
decreased by treatment with crude KV, and two KV fractions (FI and FII), but not fraction FIII 
(Adaramoye & Adeyemi, 2006). In a long-term diabetic rat model, hypoglycemic and 
neurodegeneration-preventative activities were demonstrated in rats treated with an aqueous GK 
extract. Diabetes was induced in rats with a single injection of 60 mg/kg of STZ. GK treatment 
of diabetic rats, via oral gavage lasted for 30 days and significantly decreased glycemia levels in 
diabetic rats (Farahna et al., 2017).  
Anti-oxidative and Anti-inflammatory Properties of Garcinia kola  
 The anti-oxidative effects of KV were demonstrated in diabetic rats treated with KV by 
oral gavage at a dose of 100 mg/kg for 6 weeks. Anti-oxidative enzymes, including superoxide 
dismutase (SOD), glutathione peroxidase (GPX), and catalase (CAT), and glutathione (GSH), as 
well as the effects of apoptosis and oxygen radical absorbance capacity (ORAC) were measured. 
Significant reductions in CAT, SOD, ORAC, and apoptosis activity were found in diabetic rats 
treated with KV (Oyenihi et al., 2015). Similarly, anti-oxidative enzymes, ORAC, pro and anti-
inflammatory cytokines were measured in diabetic rats treated with KV by gastric gavage for 6 
weeks. Diabetic rats treated with KV exhibited restorative levels of CAT and GSH, and a 
significant increase of ORAC. Similarly, diabetic rats treated with GK seeds at a dose of 250 
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mg/kg for 2 weeks demonstrated a significant restoration of antioxidant enzymes (Adedara et al., 
2015).  A reduction of pro-inflammatory cytokines, such as IL-1 and TNFα, with a slight 
increasing trend of IL-10, were also observed in diabetic KV-treated rats (Ayepola, Cerf, Brooks, 
& Oguntibeju, 2014).  A study that measured anti-oxidant and anti-inflammatory markers in the 
blood of diabetic rats treated with 100 mg/kg KV by oral gavage for 6 weeks found an increasing 
trend of ferric-reducing antioxidant power (FRAP), and a reduction of IL-1, monocyte 
chemotactic protein-1 (MCP-1) and vascular endothelial growth factor (VEGF) (Ayepola et al., 
2014).  
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Chapter II: Aim and Hypothesis 
The goal of this study was to evaluate the effects of GKE on the development of 
autoimmune experimental T1D in MLDSTZ-treated C57BL/6J mice. Previous studies have 
described the hypoglycemic, anti-inflammatory, and anti-oxidant properties of GKE, however, 
GKE effects on immune cell populations, primarily T cell level and their function, have never 
been studied. In addition, all of the previous studies performed GKE treatment via oral gavage, 
and not through drinking water, which physiologically resembles the natural way how this seed 
is consumed in humans. Based on the previously described hypoglycemic and anti-inflammatory 
properties of GKE, it was hypothesized that GKE will decrease the incidence, prevalence, and 
severity of T1D through its anti-inflammatory action on pathogenic T cells.  Thus, besides 
studies of glycemia levels and diabetes incidence, the effects on T cell populations/subpopulation 
levels, and their function, were studied in GKE-treated mice during the induction of 
experimental autoimmune diabetes in C57BL/6J mice. 
 
 
 
 
 
 
 
20 
 
Chapter III: Methods 
Mice 
The C57BL/6J and NOD/LtJ mouse strains were purchased from the Jackson Laboratory 
(Bar Harbor, ME, USA) and bred in the St. Cloud State University (SCSU) Vivarium. All 
procedures performed on the mice were approved by the Institutional Animal Care and Use 
Committee before the start of this project (Protocol Number 5-98). BPA free cages were used for 
housing, and mice were allowed free access for water and food with casein-based phytoestrogen-
free diet (AIN-93G Rodent Diets, Research Diet, Inc., Harlan research laboratories). Mice were 
exposed to a 12-hour light/dark cycle, and were kept in separate sexed cages, until chosen for the 
experiment based on age. Seven-week-old male C57BL/6J and four-week-old female NOD/LtJ 
mice were used for experiments. Mice were observed before and throughout the entire 
experimental period to ensure the absence of health issues or illnesses. During the experimental 
endpoints and/or upon detection of detrimental health issues, mice were euthanized via CO2 
asphyxiation.  
GK Seeds and GK Extraction 
Garcinia kola seeds were kindly provided by Dr. Oladele Gazal, and were purchased in 
Ijebu-Ode, Ogun State, Nigeria. The seeds were verified in the Department of Forestry and 
Wildlife Management, Federal University of Agriculture, Abeokuta, Ogun State, Nigeria. For 
one experiment, new seeds were purchased from the vendor, Veroex, through Amazon.com. The 
outer brown layer Garcinia kola seeds were peeled, the seeds chopped, and the seed pieces dried 
at room temperature for 4-5 days. The dried seeds were pulverized into a fine powder. A stock 
GKE solution of 40 mg/ml was prepared via aqueous extraction per the methods of Ogunmoyole, 
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Olaekan, Fatai, Makun, and Kade, with modifications. A 1:5 w:v ratio of Garcinia kola seeds 
was added to autoclaved, DI water, followed by 48 hours of maceration at 4°C. This solution was 
filtered through Whatman filter paper, and the filtrate dried for 72 hours at 37°C. GKE was 
collected and weighed, and the appropriate amount of autoclaved-DI water was added to make a 
stock solution of 40 mg/ml. The solution was divided into aliquots which were placed in a -20°C 
freezer for further use. Ethanol extractions were prepared via the method described by 
Ogunmoyole, et al., with modifications (Ogunmoyole et al., 2012). A 1:5 (w:v) ratio of Garcinia 
kola seeds was added to 100% ethanol, followed by 24 hours of room temperature maceration. 
The solution was filtered with Whatman filter paper, and prior to collection, a 24-hour 
evaporation period was allowed to ensure there is no ethanol remaining. A GKE stock solution of 
40 mg/ml was prepared with the addition of DMSO (Sigma-Aldrich, USA); GKE stock was 
divided into aliquots and stored at room temperature for further use.  
GKE Treatment 
Treatment mice received a dose of 100 mg/kg of either aqueous or ethanol GKE. To 
ensure mice received the proper dosage, the amount of GKE stock solution was altered per the 
current average body weight. Control mice for aqueous GKE extract groups received cold, 
autoclaved DI water, and control mice in ethanol extracted GKE groups received autoclaved DI 
water with the addition of 1.8% DMSO. Water levels were monitored daily and were filled 
accordingly; water bottles were replaced weekly, and mice received new GKE-treated and 
control water every 4-5 days.  
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Liquid-Chromatography Mass Spectrophotometry (LC-MS) Analysis of GKE 
 Three aqueous and two ethanol samples of GKE, each obtained during a separate 
extraction procedure, were sent to the University of Iowa for LC-MS analysis. 100ul of each 
sample was diluted into a ml of 90/10 H2O/ACN. The liquid chromatogram column used was a 
Zorbax Eclipse C18 (2.1 x 150 mm). The gradient started at 95% water that ramped up to 100% 
ACN over 20 minutes. The instrument used was a Waters QTOF Premier with an Acquity UPLC 
and Acquity TUV; wavelengths of 254 nm and 240 nm were used on the TUV. Mass 
spectrophotometry data was collected using positive ion electrospray ionization (ESI).  
Induction of MLDSTZ-T1D in C57BL/6 Mice 
 STZ was administered intraperitonially for five consecutive days at a low dose of 40 
mg/kg to both control and GKE treated mice. STZ was prepared daily before each injection by 
dissolving it in 0.05 M sodium citrate buffer (147.1 mg sodium citrate in 10 mL cold DI H2O). 
The buffer pH was set to 4.5, and was properly adjusted by the addition of either 1 M HCl or 1 
M NaOH. This solution was vortexed to create a drug suspension. Injections were done at a 
volume of 6.52 uL/g of body weight, as previously described (ter Veld et al., 2008). STZ 
administrations were completed within 15 minutes to avoid drug denaturation.  
Glycemia Measurements 
 Initial glycemia and body weight measurements were done prior STZ injections and 
continued biweekly at 9 weeks of age until the experimental endpoint. Glycemia measurements 
were done with the Accu-Chek Aviva glucometer (Roche Diagnostics, Indianapolis, IN, USA). 
Mice were held in 50 mL Falcon tubes with breathing holes drilled on the sides and on the cap; 
the tails were placed into a warm water bath to induce vasodilation of the lateral vein. A single 
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blood drop, approximately 0.6 uL, was obtained by poking a vein, and was placed on the Accu-
Chek Aviva glucose strips. Mice were considered diabetic when there were two consecutive 
glycemia measurements of 250 mg/dL or greater, with the first one considered as the day of 
diabetes onset. 
Preparation of a Single Cell Suspension from the Spleen 
 Mice were euthanized via CO2 asphyxiation at the determined experimental endpoints, 
and spleens were aseptically harvested. Single cell suspensions were prepared by mashing the 
spleens with a plunger from a 10-mL syringe and a passage through 40 um nylon strainers (BD 
Falcon, USA). Suspensions were centrifuged at 1200 rpm for 5 minutes. The supernatant was 
decanted, and the cell pellet was resuspended in 750 uL of ACK lysis buffer (NH4Cl 8.29g/L, 
KHCO3 1.0g/L, EDTA Na2· 2H2O 0.0375g/L; 18 Lonza Bio Whittaker, Walkersville, MD, 
USA) for 1-minute for complete hemolysis. An additional 5 mL of 1X PBS was added to stop 
the action of the lysis buffer, and the suspensions were centrifuged. Three additional washes with 
5 ml 1X PBS and subsequent centrifugation were done to remove cell debris and washout the 
ACK buffer. Cells counts, and viability were done via Trypan Blue (Lonza Bio Whittaker 
Walkersville, MD, USA) exclusion method.  Briefly, the isolated splenocytes were prepared in a 
1:20 dilution with Trypan Blue and were loaded in a hemocytometer; the loaded hemocytometer 
was put under 10x magnification objective of a microscope to determine live and dead cell by 
counting all cells in two opposing quadrants. Dead cells appear blue and alive cells yellow. 
T Cell Proliferation Assay 
 Proliferation assays were done to determine the ex vivo effects of GKE treatment on T 
cell function. Single cell suspensions, obtained from the spleens of mice post in vivo treatment 
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by aqueous or ethanol GKE, were diluted in the culturing medium [RPMI-1640 with 5 units 
Penicillin and Streptomycin and 10% Fetal Bovine Serum (Sigma, St. Louis, MO,USA)]. 
Splenocytes were plated in a 96 well plate in a concentration of 4x105 in a total volume of 100 
uL. Selected wells received the addition of the T-cell mitogen Concanavalin A (3 ug/mL) [(Con 
A) Sigma, St. Louis, MO, USA], non-stimulated wells received additional complete media. 
Plates incubated for 72 hours at 37°C with 5% CO2. ConA specifically stimulates the 
proliferation of T cells. At the end of the culturing period, the Alamar blue assay was utilized to 
quantify T cell proliferation (Invitrogen, Grand Island, NY, USA). Alamar blue is a colorimetric 
assay which measures reducing capacity of cells. The active ingredient, resazurin (7-hydroxy-10-
oxidophenoxazin-10-ium-3-one) is reduced to fluorescent pink resorufin (Rampersad, 2012).  
Ten uL of Alamar blue was added to the wells. The plate incubated for an additional 5-6 hours 
under the conditions previously described and read by a spectrophotometer at 570 nm to obtain 
the optical density.  
Characterization of Immune Cell Populations (Immunophenotyping) 
Flow cytometry was done to determine immune cell composition (T cells and respective 
subtypes, B cells, macrophages, and NK cells) post GKE treatment. Isolated splenocytes from 
single cell suspensions were used at a concentration of 1x106 and were transferred to FACS 
tubes with the addition of 1 ml FACS buffer (1% FBS, PBS, 0.1% NaN3). Splenocytes were 
centrifuged for 5 minutes at 1200 rpm at 4°C, supernatant was discarded, and tubes were blotted 
to rid excess buffer. To determine immune cell populations, splenocytes were stained with 
fluorochrome-conjugated antibodies that bind to specific CD markers Antibodies were prepared 
with FACS buffer in a ratio of 1:100, and splenocytes incubated with the addition of antibodies 
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for 30-45 minutes at 4°C protected from light. The CDs that classify all T cells, Th, Tc, Treg, B 
cells, macrophages, and NK cells are respectively: CD3, CD4, CD8, CD4/CD25, CD45R/B220, 
NK1.1b, and CD11b. Antibodies were conjugated with the following fluorochromes: fluoroscein 
isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll (PerCP), and allophycocyanin 
(APC). The following fluorochrome-conjugated antibodies were used for flow cytometry: anti-
CD4 PerCP (clone RM4-5), anti-CD8 FITC (clone 53-6.7), anti-CD25 APC (clone 3C7), anti-
B220 APC (clone RA3-6B2), anti-NK 1.1 FITC (clone PK 136), anti-CD 11b PerCP (clone 
M1/70), and anti- CD3 PE (clone 145-2C11) (BD Biosciences). After incubation, cells were 
washed three times with FACS buffer; an additional 300 uL of FACS buffer was added to the 
samples before an acquisition of cells by the flow cytometer.  
Cytokine Collection and Analysis 
Isolated splenocytes were cultured in a 24-well plate at a concentration of 2x106 in 500 
uL Selected wells received Con A, and other wells received additional complete media, for a 
total volume of 1 mL. The plates were incubated for 48 hours under conditions previously 
described. Once the incubation period was completed, the plate was spun down in a centrifuge 
for 10 minutes at 1200 rpm, 4°C the supernatant was collected in 250 uL aliquots, and  stored at -
80°c. Cytokine quantification was done via the CBA Mouse Th1/Th2/Th17 cytokine kit (BD 
Biosciences, USA); cytokines of interest included IL-2, IL-4, IL-6, IL-10, IL-17, IFNγ, and 
TNFα. Briefly, lyophilized mouse standards were reconstituted with 2.0 mL of assay diluent, 
followed by a serial dilution that was performed  in a ratio of 1:2 through the final dilution of 
1:256. The total bead capture solution was prepared by the addition of 10 uL of each cytokine, 
50 uL of this solution was added to each dilution tube, with the addition of 50 uL of cell 
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supernatant. 50 uL of the fluorochrome, PE, was also added, and the samples incubated for 2 
hours at room temperature, protected from light. Acquisition was done by flow cytometer, and 
samples were analyzed using FCAP array software (Softflow, New Brighton, MN, USA).  
Assessment of T Cell Proliferation and Cytokine Levels 
The effects of GKE on T-cell proliferation and cytokine secretion were tested in vitro. 
Single cell suspensions were prepared from the spleens of non-treated C57BL/6J mice as 
previously described. Proliferation assays were done to investigate the effects of aqueous GKE 
on in vitro T-cell proliferation. Cultured splenocytes with suitable cell counts in a concentration 
of 4x105 were plated in a 96-well plate in a total volume of 100 ul. Selected wells were cultured 
in ConA and the addition of GKE from 2 ug/mL to 1 mg/mL. Select non-stimulated wells 
received additional complete media and GKE (1 mg/mL). When investigating the effects of 
ethanol extracted GKE, appropriate DMSO controls were included to account for the 
immunosuppressive activity of DMSO at high concentrations. The culture plates incubated for 
72 hours, 37°C with 5% CO2, and received 10 uL of Alamar blue with an additional 5-6 hours of 
incubation as previously described. The optical density was determined by reading the plate at 
570 nm. Isolated splenocytes were cultured in a 24-well plate at a concentration of 4x105 in 500 
ul. Selected wells received Con A, and GKE at low concentrations (2 ug/mL and 4 ug/mL) and 
high concentrations (250 ug/mL, 500 ug/mL, and 1 mg/mL) and other wells received additional 
complete media, for a total volume of 1 mL; the culture plate incubated for 48 hours under 
conditions previously described. Once the incubation period was completed, the plate was spun 
down in a centrifuge for 10 minutes at 1200 rpm, 4°C the supernatant was collected in 250 uL 
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aliquots and were stored at -80°C. Cytokine quantification was done via the CBA Mouse 
Th1/Th2/Th17 cytokine kit (BD Biosciences, USA). 
Statistical Analysis  
 Diabetes incidence of control and GKE treated mice were analyzed using a survival 
analysis statistical method (JMP, SAS, Cary, NC, USA). Glycemia and body weight 
measurements were analyzed using a one-way ANOVA with repeated measures (significance 
was considered as p<0.05 for both measures). Differences in T cell proliferation (both non-
stimulated and stimulated), and immune cell composition between control and GKE treated mice 
were analyzed with a two-tailed, unpaired student’s T-test (significance defined as p<0.05). 
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Chapter IV: Results 
In Vitro Effects of Aqueous GKE on T Cell Proliferation and T Cell Cytokine Profiles 
 The potential direct effects of aqueous GKE on T cells were studied through analysis of T 
cell function and cytokine profiles using splenocytes of male and female C57BL/6J mice. A 
serial dilution of aqueous GKE, concentrations ranging from 2 ug/mL to 1 mg/mL, was added to 
C57BL/6 splenocyte cultures stimulated with Con A (3 ug/mL). There was no significant effect 
observed at any GKE concentration on T cell proliferation (Figure 2). In addition, cytokine 
analysis was performed in cultured Con A-stimulated splenocytes exposed to low and high 
concentrations of GKE. High concentrations of GKE ranged from 250 ug/mL to 1 mg/mL, low 
concentrations were 2 ug/mL and 4 ug/mL; selected splenocyte cultures did not receive GKE and 
served as a control. There were no significant differences in IL-10, IL-2, or IFNγ secretion 
amongst all concentrations of GKE tested (Figures 3B, 3D, 3F). IL-17A was significantly 
increased amongst the two highest concentrations of GKE compared to the two lowest 
concentrations and the control (Figure 3A). TNFα concentration obtained in T cell cultures 
exposed to GKE at 1 mg/mL was significantly increased compared to those exposed to GKE at 
250 ug/mL, 4 ug/mL, 2 ug/mL and the control (Figure 3C). IL-4 was significantly increased in 
cultures treated by GKE 1 mg/mL compared to 4 ug/mL (Figure 3E). IL-6 level was significantly 
increased in GKE 1 mg/mL-treated splenocytes compared to those cultured with addition of 
GKE in the concentration of 4 ug/mL, 2 ug/mL and the control (Figure 3G). 
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Figure 2. T cell proliferative index of C57BL/6J splenocytes cultured with a serial dilution of 
aqueous GKE. Proliferation index was calculated by dividing the optical densities of Con A-
stimulated by optical densities of non-stimulated T cells. Data presented as average ± SEM, n=3.  
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Figure 3. Concentration of cytokines obtained in Con A-stimulated C57BL/6 splenocytes 
cultured with different concentrations of GKE. A. IL-17; B. IL-10; C. TNFα; D. IFNγ; E. IL-4; 
F. IL-2; G. IL-6.  Data presented as average ± SEM; n=2; * p< 0.05 compared to 0, 2, and 4 
ug/mL GKE (A); compared to 0, 2, 4, and 250 ug/mL GKE (C); compared to 4 ug/mL GKE (E). 
* p< 0.05 compared to 0, 2, and 4 ug/mL (A); compared to 0, 2, 4, 250 ug/mL GKE (C). *p< 
0.05 compared to 4 ug/mL GKE. 
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In Vivo Examination of Aqueous GKE Treatment Effects on Incidence  
and Glycemia Levels in MLDSTZ Model of T1D 
 
 Seven-week-old male C57BL/6J mice were treated with aqueous GKE (100 mg/kg) in 
their drinking water until 13 weeks of age. At eight weeks of age, mice were intraperitoneally 
injected with multiple, low-doses (40 mg/kg) of streptozotocin (MLDSTZ) for five days. Body 
weight and glucose levels were measured on the third day before STZ injections, and biweekly 
from the eighth day after the first STZ injection, until the experimental endpoint on day 30 (or 13 
weeks of age). Glycemia and body weight measurements were also done in mice that were 
treated with aqueous GKE but did not receive STZ injections (STZ-free mice). GKE treatment 
did not exhibit significant effects on glycemia levels in MLDSTZ mice (Figure 4A). However, 
GKE had significantly increased body weight (p= 0.0091) in treated mice compared to their 
controls (Figure 4B). In addition, GKE treatment did not slow down diabetes development in 
STZ-exposed mice (an average day of diabetes occurrence ± SEM for GKE treatment group was 
14.6 ± 1.0 vs. 17.1 ± 1.5 days for control group), nor reduced disease incidence, as 84% of the 
aqueous GKE-treated mice and 73% and of the control mice were diabetic by the experimental 
endpoint (Figure 4C).  
            In STZ-free, non-diabetic mice, GKE had no effect on glycemia levels (Figure 4A); STZ-
free mice treated with GKE had a trend of decrease in body weight compared to their controls 
(Figure 4B). 
  Since no effect on glycemia or diabetes incidence was observed in our initial 
experiments with aqueous GKE, we questioned the quality and freshness of Garcinia kola seeds 
we used. Thus, fresh seeds were purchased from the other source. The aqueous GKE was 
extracted and administered a week before the STZ injections to mice, as described previously. 
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This aqueous GKE treatment, which lasted for 15 days post first STZ injection, did not exhibit 
significant effect on body weight, glycemia levels (data not shown), or diabetes incidence of 
treated mice compared to controls (an average day of diabetes occurrence ± SEM for GKE 
treatment group was 10.5 ± 0.6 vs. 11.0 ± 0.1 days for control group). In addition, we also 
questioned our GKE administration protocol, in which fresh GKE treatment water was prepared 
every five days. Thus, a pilot experiment was performed in which the aqueous GKE treatment 
water was prepared daily from a GKE stock solution, and given a week before the STZ 
administration to MLDSTZ mice for drinking. The mice were followed until day 22 post first 
STZ injection. This treatment had no effect on either body weight and glycemia levels (Figure 
5A and 5B), nor on diabetes development (an average day of diabetes occurrence ± SEM for 
GKE treatment group was 10.5 ± 0.5 vs. 11.8 ± 1.1 days for control group). 
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Figure 4. Average glycemia (A), body weight (B), and diabetes incidence (C) of MLDSTZ and 
STZ-free C57BL/6J mice treated with aqueous GKE for six weeks. (A) Glycemia measurements 
started three days before and lasted until 30 days after the initial STZ injection. Data presented as 
average ± SEM. (B) Body weights measurements started three days before the initial STZ 
injection and lasted until the experimental endpoint. Data presented as average ± SEM, *p<0.05 
compared to control mice. (C) Diabetes incidence presented as the percentage of diabetes-free 
mice. Diabetes was defined as having two consecutive measurements of glycemia of 250 mg/dL 
or greater. C and C+G groups were not graphed, as they stayed 100% diabetes-free throughout 
the experiment; C-control, STZ-free mice; C+G-control, STZ-free mice treated by GKE; S-
control MLDSTZ mice, and S+G-MLDSTZ mice treated by GKE. 
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Figure 5. Average body weight (A) and glycemia (B) for MLDSTZ mice treated with fresh, 
daily aqueous GKE for four weeks. (A) Body weight measurements started three days before 
STZ injections and continued biweekly until 22 days after the first STZ injection. Data presented 
as average ± SEM. (B) Glycemia measurements started three days before STZ injections and 
continued biweekly until 22 days after the first STZ injection. Data presented as average ± SEM. 
Effects of Aqueous GKE on Immune Parameters During T1D Development 
 Mice were sacrificed at two time points, on days 11 and 30 post the initial STZ injection, 
to evaluate aqueous GKE’s effects on immune parameters, such as: splenic cell counts and 
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viability, T cell proliferation (presented as proliferation index), T cell sub-populations, and 
cytokine profiles.  
           The following data were obtained from the spleens of MLDSTZ mice treated with 
aqueous GKE and their controls on day 11. GKE treatment did not significantly affect the cell 
counts or cell viability (Figures 6A and 6B). There was a trend of decrease in T cell proliferation 
in GKE-treated mice compared to controls (Figure 7). Immunophenotyping of spleens obtained 
from mice treated with GKE, presented as a percentage, showed significant decreases in T, Th, 
Tc, Treg, and MAC cells (p= 0002, p< 0.0001, p= 0.001, p= 0.001, and p=0.001, respectively), 
whereas B cells were significantly increased (p= 0.0001), compared to the controls (Figure 8A). 
Immunophenotypes, in terms of total cell counts, showed that GKE treatment significantly 
decreased MAC and NK cells (p= 0.04 and p= 0.04) and induced a trend of decrease in T cells 
and T cell subtypes, compared to controls (Figure 8B). Cytokine measurements showed 
significant increases in TNFα, IFNγ, and IL-6 (p= 0.003, p= 0.03, and p= 0.02, respectively), and 
a significant decrease in IL-2 (p= 0.02) in mice treated with GKE compared to their controls 
(Figure 9).   
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Figure 6. Total splenocyte counts (A) and cell viability (B) obtained on day 11 from MLDSTZ 
C57BL/6J mice treated with aqueous GKE. (A) Cell counts, and viability were measured using 
the Trypan blue exclusion method. Data presented as average ± SEM. (B) Cell viability was 
calculated by dividing alive cells by total cells x 100. Data presented as average ± SEM. The 
treatment groups’ legend described in Figure 3. 
 
Figure 7. T cell proliferative index obtained on day 11 from the spleens of MLDSTZ C57BL/6J 
mice treated with aqueous GKE. T cell proliferation was induced by Con A stimulation during a 
72-hour culture period and optical density was measured by an Alamar Blue assay. Proliferation 
index was obtained by dividing optical densities measured in ConA-stimulated by non-
stimulated cells. Data presented as average ± SEM. The treatment groups’ legend described in 
Figure 3. 
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Figure 8. Immunophenotyping of splenocytes obtained on day 11 from MLDSTZ C57BL/6J 
mice treated with aqueous GKE. Immunophenotypes presented as percentages (A) and total cell 
counts (B). Data presented as average ± SEM, *p<0.05 compared to own, respective control 
group of mice for each particular cell type. The treatment groups’ legend described in Figure 3. 
 
B 
A 
40 
 
 
Figure 9. Cytokine profiles of splenocytes, obtained on day 11, from MLDSTZ C57BL/6J mice 
treated with aqueous GKE. Data presented as average ± SEM, *p<0.05 compared to own control 
group of mice. The treatment groups’ legend described in Figure 3 
The following data were obtained in MLDSTZ mice, treated with aqueous GKE and 
controls, on day 30. There were no significant effects on cell counts, nor cell viability in aqueous 
GKE-treated mice compared to their controls (Figures 10A and 10B). There was a trend of 
decrease in T cell proliferation of GKE-treated mice compared to controls (Figure 11). 
Immunophenotyping of MLDSTZ mice treated with GKE, presented as percentages, showed 
significant decreases in T, Th, Tc, and NK cells, respectively (p= 0.004, p= 0.02, p= 0.02, and p= 
0.0007, respectively), and a significant increase in B cells (p= 0.003), compared to controls 
(Figure 12A). In terms of total cell counts, immunophenotyping showed trends of decrease in T 
cells and respective subtypes, and a trend of increase in B cells, in mice treated with GKE 
(Figure 12B). The cytokine profiles, obtained from GKE-treated mice, revealed a significant 
increase (p= 0.03) in IL-10, a trend in elevated levels of TNFα and IL-6, and a non-significant 
reduction of IL-2, compared to controls (Figure 13).  
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 Next, we asked whether GKE treatment per se would induce the effects on immune 
parameters observed in MLDSTZ model. Thus, non-diabetic, STZ-free C57BL/6 mice, were 
treated with aqueous GKE from seven- to 13 weeks of age (end point was equivalent to day 30 
endpoint post first STZ injection in MLDSTZ mice). GKE treatment did not change the splenic 
cell counts or cell viability (Figures 10A and 10B). There was a significant decrease (p= 0.025) 
in T cell proliferation observed in STZ-free mice treated with GKE compared to their controls 
(Figure 11). Immunophenotyping of spleens obtained from mice treated with GKE, presented as 
percentages, showed significant decreases in T, Th, Tc, and MAC cells (p= 0.01, p= 0.003, p= 
0.03, and p=0.02, respectively); while B cells were significantly increased (p= 0.01), compared 
to controls (Figure 12A). There were no significant effects of GKE observed on 
immunophenotypes in terms of total cell counts, but there were trends of decrease observed 
among T cells and their subtypes, and a trend of increase in B cells (Figure 12B). The cytokine 
measurements showed significant increases in IL-10, and IFNγ (p= 0.001 and p= 0.001), and a 
significant decrease in IL-2 (p= 0.01). Though not statistically significant, there was an increase 
of TNFα and IL-6 (Figure 13).  
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Figure 10. Total splenocyte counts (A) and cell viability (B) obtained on day 30 from MLDSTZ 
and STZ-free C57BL/6J mice treated with aqueous GKE from seven to 13 weeks of age. (A) 
Cell counts and viability were measured using the Trypan blue exclusion method. Data presented 
as average ± SEM. (B) Cell viability was calculated by dividing alive cells by total cells x 100. 
Data presented as average ± SEM. The treatment groups’ legend described in Figure 3. 
 
A 
B 
43 
 
 
 
 
 
 
 
 
  
 
Figure 11. T cell proliferative index obtained on day 30 from the spleens of MLDSTZ and STZ-
free C57BL/6J mice treated with aqueous GKE from seven to 13 weeks of age. T cell 
proliferation was induced by Con A stimulation during a 72-hour culture period and optical 
density was measured by an Alamar Blue assay. Proliferation index was obtained by dividing 
optical densities measured in ConA-stimulated by non-stimulated cells. Data presented as 
average ± SEM,*p<0.05 compared to control mice. The treatment groups’ legend described in 
Figure 3. 
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Figure 12. Immunophenotyping of splenocytes obtained on day 30 from MLDSTZ and STZ-free 
C57BL/6J mice treated with aqueous GKE from seven to 13 weeks of age. Immunophenotypes 
presented as percentages (A) and total cell counts (B). Data presented as average ± SEM, 
*p<0.05 compared to own, respective control group of mice for each particular cell type. The 
treatment groups’ legend described in Figure 3. 
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Figure 13. Cytokine profiles of splenocytes obtained on day 30 from MLDSTZ and STZ-free 
C57BL/6J mice treated with aqueous GKE from seven to 13 weeks of age. Data presented as 
average ± SEM, *p<0.05 compared to own control group of mice. The treatment groups’ legend 
described in Figure 3. 
In Vitro Effects of Ethanol GKE on T Cell Proliferation 
 Since aqueous GKE did not affect T cell proliferation in vitro, while influencing cytokine 
secretion, we wanted to study whether ethanol GKE would exhibit similar or different effects on 
T cells cultures. C57BL/6J splenocytes were stimulated with Con A (3 ug/mL) and GKE was 
added ranging in concentrations from 2 ug/mL to 1 mg/mL. As ethanol GKE stock was prepared 
in DMSO, and higher concentrations of DMSO are known to induce suppression of T cell 
proliferation (Cetkovic-Cvrlje, Olson, Schindler, & Gong, 2015), selected control cells, that did 
not receive GKE, were cultured with an equivalent amount of DMSO present in the higher GKE 
concentrations of 250 ug/mL, 500 ug/mL, and 1 mg/mL. Proliferation of splenocytes cultured 
with GKE at 250 ug/mL was significantly lower compared to its control DMSO equivalent. In 
contrast, T cell proliferation was significantly increased in splenocytes treated with GKE at 1 
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mg/mL compared to the DMSO equivalent of 1 mg/mL, whereas 500 ug/mL GKE did not affect 
T cell proliferation at all (Figure 14). Lower concentrations of GKE had no effect on T cell 
function.  
 
Figure 14. In vitro proliferation indices of stimulated splenocytes from C57BL/6J mice cultured 
with a serial dilution of GKE (blue bars). Select stimulated splenocytes received concentrations 
of DMSO that were equivalent to the DMSO content in the three highest GKE concentrations 
(purple bars). Data presented as average ± SEM, n=3, * p< 0.05. indicates significant difference 
compared to respective DMSO control. 
Effects of In Vivo Ethanol GKE Treatment on Glycemia and Diabetes Incidence in 
MLDSTZ Model for T1D 
A new set of experiments were performed in order to study effects of ethanol GKE on the 
diabetes development and glycemia. Seven-week-old male C57BL/6J mice were treated with 
ethanol GKE (100 mg/kg) in their drinking water until 13 weeks of age. Since GKE stock was 
prepared in DMSO, control mice received water enriched with 1.8% DMSO, the same DMSO 
concentration present in the GKE treatment water. At eight weeks of age, mice were 
intraperitoneally injected with multiple, low-doses (40 mg/kg) of streptozotocin (MLDSTZ) for 
five days. Body weight and glucose levels were measured the third day before STZ injections 
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and continued biweekly eight days after injections, until the experimental endpoint of 30 days 
after the first STZ injection (13 weeks of age). Glycemia and body weight measurements were 
also done in mice that were treated with ethanol GKE but did not receive STZ injections (STZ-
free mice). GKE had no effect on glycemia levels nor body weight in MLDSTZ mice compared 
to their controls (Figure 15A & 15B). Treatment with ethanol GKE did not delay disease 
occurrence nor reduce incidence of disease. Diabetes occurred on an average of 19.8 ± 1.5 days 
for GKE treated mice and 19.4 ± 1.9 days for control mice. By the experimental endpoint, 92% 
of ethanol GKE-treated mice were diabetic and 83% of control mice were diabetic (Figure 15C).  
Interestingly, STZ-free, non-diabetic mice treated with ethanol GKE had significantly 
increased glycemia levels compared to their controls (p= 0.0017), whereas GKE had no effect on 
body weight in these mice (Figure 15A and 15B).  
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Figure 15. Average glycemia (A), average body weight (B), and diabetes incidence (C) of male 
MLDSTZ C57BL/6J mice and non-injected mice treated with ethanol GKE for six weeks. (A) 
Glycemia measurements were done beginning on the eighth day post the initial STZ injection up 
until 30 days after the initial STZ injection. Diabetes was defined as having two consecutive 
measurements of 250 mg/dL or greater. Data presented as average ± SEM, *p<0.05 compared to 
control mice. (B) Body weights measurements started three days before the initial STZ injection 
and lasted until the experimental endpoint. Data presented as average ± SEM. (C) Diabetes 
incidence presented as the percentage of diabetes-free mice. Diabetes was defined as having two 
consecutive measurements of glycemia of 250 mg/dL or greater. C and C+G groups were not 
graphed, as they stayed 100% diabetes-free throughout the experiment; The treatment groups’ 
legend described in Figure 3, with a notion that G here represents ethanol GKE treatment. 
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Effects of Ethanol GKE on Immune Parameters During T1D Development 
 Mice were sacrificed at two time points – on days 11 and 30 post the initial STZ injection 
to evaluate ethanol GKE’s effects on immune parameters such as: cell counts and viability, T cell 
proliferation (presented as proliferation index), T cell populations, and cytokine profiles. The 
following data are obtained from mice treated with ethanol GKE and controls on day 11. There 
were no significant effects on cell counts, cell viability (Figure 16A and 16B), or T cell 
proliferation (Figure 17) in mice treated with ethanol GKE compared to their controls. 
Immunophenotyping, presented as a percentage for a particular cell type, showed significant 
decreases in T, Th, Tc, and NK cells (p= 0.006, p= 0.03, p= 0.04, and p= 0.01, respectively), and 
a significant increase in B cells (p= 0.001) in GKE treated mice compared to their controls 
(Figure 18A). Immunophenotyping, presented in terms of total cell counts, exhibited significant 
decreases in T, Th, and NK cells (p= 0.01, p= 0.01, and p= 0.04 respectively), and trends of 
decrease in Tc, Tr, and MAC cells (Figure 18B) in mice treated with GKE compared to control 
mice. There were significant increases in IL-17A, IL-10, TNFα, and IL-6 (p= 0.01, p= 0.001, p= 
0.01 and p= 0.01, respectively), and a significant decrease in IL-2 secretion (p= 0.005), obtained 
from the spleens of  ethanol GKE-treated mice compared to controls; there was also a trend of 
increase in IFNγ in GKE-treated group of mice (Figure 19). 
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Figure 16. Total splenocyte counts (A) and cell viability (B) obtained on day 11 from MLDSTZ 
C57BL/6J mice treated with ethanol GKE. (A) Cell counts, and viability were measured using 
the Trypan blue exclusion method. Data presented as average ± SEM. (B) Cell viability was 
calculated by dividing alive cells by total cells x 100. Data presented as average ± SEM. The 
treatment groups’ legend described in Figure 14.  
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Figure 17. T cell proliferative index obtained on day 30 from the spleens of MLDSTZ C57BL/6J 
mice treated with ethanol GKE. T cell proliferation was induced by Con A stimulation during a 
72-hour culture period and optical density was measured by an Alamar Blue assay. Proliferation 
index was obtained by dividing optical densities measured in ConA-stimulated by non-
stimulated cells. Data presented as average ± SEM. The treatment groups’ legend described in 
Figure 14.  
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Figure 18. Immunophenotyping of splenocytes obtained on day 11 from MLDSTZ C57BL/6J 
mice treated with ethanol GKE. Immunophenotypes presented as percentages (A) and total cell 
counts (B). Data presented as average ± SEM, *p<0.05 compared to own, respective control 
group of mice for each particular cell type. The treatment groups’ legend described in Figure 14. 
 
 
Figure 19. Cytokine profiles of splenocytes obtained on day 11 from MLDSTZ C57BL/6J mice 
treated with ethanol GKE. Data presented as average ± SEM, *p< 0.05 compared to control 
mice. The treatment groups’ legend described in Figure 14. 
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The following data are from MLDSTZ mice treated with ethanol GKE and their controls 
on day 30. There were no significant effects observed on cell counts, cell viability, or T cell 
proliferation in mice treated with ethanol GKE compared to their controls (Figures 20A, 20B, 
and 21). Immunophenotyping, presented as a percentage, showed significant decreases in T, Th, 
Treg, B, and MAC cells (p= 0.01, p=0.01, p= 0.02, p=0.008, and p= 0.03, respectively) in mice 
treated with GKE compared to their controls (Figure 22A). There was also observed a trend of 
reduction in Tc in MLDSTZ mice treated with ethanol GKE compared to controls. 
Immunophenotyping in terms of total cell counts, showed significant decreases in T, Th, Tc, and 
Treg cells (p= 0.008, p= 0.01, p= 0.02, and p= 0.01, respectively) in GKE-treated mice compared 
to their controls (Figure 22B). There were trends of increase in TNFα, IFNγ, and IL-6, and a 
trend of reduction in IL-2 in ethanol GKE-treated MLDSTZ mice compared to controls (Figure 
23).  
The following data were obtained from STZ-free mice treated with ethanol GKE from 
seven to 13 weeks of age (equivalent to the day 30 timepoint ). GKE significantly increased 
splenic cell counts (p= 0.018), while having no effect on cell viability, compared to control mice 
(Figure 20A and 20B). There was a trend of decrease in T cell proliferation in ethanol GKE-
treated mice compared to controls (Figure 21). Immunophenotyping, presented as a percentage, 
showed significant decreases in all T and Tc cells (p= 0.01 and p= 0.02), and an increase in B 
cells (p= 0.004) in GKE-treated mice compared to their controls (Figure 22A). There was also a 
trend of decrease in NK and MAC cells in mice treated with GKE compared to controls. 
Immunophenotyping in terms of total cell counts showed a significant increase in B cells (p= 
0.002), and trends of increase in T, Th, and Tc cells in ethanol GKE-treated mice compared to 
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their controls (Figure 22B). There were trends of increase in IL-17A, IL-10, TNFα, IFNγ, and 
IL-6, and a trend of reduction in IL-2 in STZ-free mice treated with ethanol GKE compared to 
controls (Figure 23). 
 
 
Figure 20. Total splenocyte counts (A) and cell viability (B) obtained on day 30 from MLDSTZ 
and STZ-free C57BL/6J mice treated with ethanol GKE from seven to 13 weeks of age. (A) Cell 
counts, and viability were measured using the Trypan blue exclusion method. Data presented as 
average ± SEM, *p<0.05 compared to control mice. (B) Cell viability was calculated by dividing 
alive cells by total cells x 100. Data presented as average ± SEM. The treatment groups’ legend 
described in Figure 14. 
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Figure 21. T cell proliferative index obtained on day 30 from the spleens of MLDSTZ and STZ-
free C57BL/6J mice treated with ethanol GKE from seven to 13 weeks of age. T cell 
proliferation was induced by Con A stimulation during a 72-hour culture period and optical 
density was measured by an Alamar Blue assay. Proliferation index was obtained by dividing 
optical densities measured in ConA-stimulated by non-stimulated cells. Data presented as 
average ± SEM. The treatment groups’ legend described in Figure 14. 
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Figure 22. Immunophenotyping of splenocytes obtained on day 30 from MLDSTZ and STZ-free 
C57BL/6J mice treated with ethanol GKE from seven to 13 weeks of age. Immunophenotypes 
presented as percentages (A) and total cell counts (B). Data presented as average ± SEM, 
*p<0.05 compared to own, respective control group of mice for each particular cell type. The 
treatment groups’ legend described in Figure 14. 
 
 
Figure 23. Cytokine profiles of splenocytes obtained on day 30 from MLDSTZ and STZ-free 
C57BL/6J mice treated with ethanol GKE from seven to 13 weeks of age. Data presented as 
average ± SEM. The treatment groups’ legend described in Figure 14. 
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Effects of In Vivo Ethanol GKE Treatment on Glycemia and Diabetes Incidence  
in NOD Mouse Model  
 Since hypoglycemic effect, as well as a reduction of disease incidence have not been 
observed in chemically-induced MLDSTZ model of T1D, we questioned whether GKE treatment 
would exhibit an effect on these parameters in NOD/LtJ females, a mouse model that 
spontaneously develops T1D. Four-week-old female NOD/LtJ mice were treated with ethanol 
GKE (100 mg/kg) in their drinking water until the experimental endpoint of 24 weeks of age. 
Control mice received water enriched with 1.8% DMSO to have the same DMSO concentration 
in their drinking water as the GKE treatment group.  Whereas no difference in efficacy in 
reduction of hyperglycemia and diabetes incidence was observed between the aqueous and 
ethanol GKE treatments, the ethanol GKE extract was chosen, as potentially more potent extract, 
for studying antidiabetic GKE effects in NOD mice. The initial body weight and glycemia 
measurements were done at four weeks of age. Biweekly body weight and glycemia 
measurements started at seven and lasted until 24 weeks of age. Diabetes was defined as having 
two consecutive measurements of 250 mg/dL or greater; mice were euthanized as they became 
diabetic. Treatment with ethanol GKE had no effect on body weight or glycemia levels (Figures 
24A and 24B). In addition, GKE had no effect on disease incidence nor disease prevalence 
(Figure 24C). Disease developed on an average of 16.6 ± 0.9 weeks in GKE-treated mice and 
15.3 ± 0.5 weeks for control mice. By the experimental endpoint of 24 weeks of age, 94% of 
mice treated with GKE were diabetic in comparison to 73% controls.  
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Figure 24. Average body weight (A), average glycemia (B), and diabetes incidence (C) of 
female NOD/LtJ mice treated with ethanol GKE for five months. (A) Body weight 
measurements continued biweekly from 7 weeks of age until the experimental endpoint at 24 
weeks of age. Data presented as average ± SEM. (B) Glycemia measurements continued 
biweekly from 7 weeks of age until the experimental endpoint at 24 weeks of age. Data 
presented as average ± SEM. (C) Diabetes incidence presented as the percentage of diabetes free 
mice. Diabetes was defined as two consecutive glycemia measurements of 250 mg/dL or greater.  
LC-MS Analysis of GKE 
 As the performed extraction method was not the primary method done in previous studies 
(Adaramoye, 2012; Ayepola et al., 2013; Iwu et al., 1990; Tchieme et al., 2016), samples of 
aqueous and ethanol GKE were sent to the University of Iowa for LC-MS analysis to confirm 
whether Kolaviron, the active biflavonoid complex, was present in our extracts. In addition, we 
wanted to know whether there would be differences between aqueous and ethanol GKE samples. 
The following compounds present in aqueous GKE were confirmed to be Garcinia biflavonoid 2 
(Figure 25B), Garcinia biflavonoid 1 (Figure 25C), kolaflavonone (Figure 25D), and binarigenin 
(Figure 25E). The same four compounds were also present in ethanol GKE (Figure 26). Thus, 
within both GKE extract types Garcinia biflavonoid 1, Garcinia biflavonoid 2, kolaflavonone, 
C 
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and binarigenin were present. The fifth flavonoid, previously found in Kolaviron (Ayepola et al., 
2013), kolaflavone, was not present in either aqueous or ethanol GKE.  
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Figure 25. LC-MS profile of an aqueous GKE sample. The first chromatography plot indicates 
retention times (A), and the subsequent four mass spectrophotograms (B-E) are from highlighted 
retention times, the following (m/z) are of compounds with 100% abundance; (B) Garcinia 
biflavonoid 2 (m/z) 575.1194, (C) Garcinia biflavonoid 1 (m/z) 559.1235, (D) kolaflavonone 
(m/z) 589.1339, and (E) binarigenin (m/z) 543.1288. 
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Figure 26. LC-MS profile of an ethanol GKE sample. The first chromatography plot indicates 
retention times (A), and the subsequent five mass spectrophotograms (B-F) are from highlighted 
retention times, the following (m/z) are of compounds with 100% abundance; (B) Garcinia 
biflavonoid 2 (m/z) 575.1190, (C) Garcinia biflavonoid 2 (m/z) 575.1194, (D) Garcinia 
biflavonoid 1 (m/z) 559.1254, (E) kolaflavonone (m/z) 589.1353, and (F) binarigenin (m/z) 
543.1299. 
Summary 
Effects of GKE treatment on glycemia, body weight, diabetes incidence, and immune 
parameters are summarized here: 
• Glycemia: Hypoglycemic effect of GKE was not observed regardless of GKE 
extraction type (aqueous or ethanol), GK seed source, frequency of freshly-prepared 
GKE treatment solution, or the experimental mouse T1D model studied (STZ-
induced MLDSTZ C57BL/6J or spontaneous NOD/LtJ). STZ-free mice treated with 
ethanol GKE had increased glycemia compared to control. 
F 
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• Body weight: There was no effect of different modalities of GKE treatment on body 
weight, tested in different types of experimental mouse models, besides an increase of 
body weights observed in MLDSTZ mice treated with aqueous GKE treatment.  
• Incidence of T1D: There was no effect of different modalities of GKE treatment on 
the incidence and prevalence of T1D obtained in MLDSTZ or NOD models of T1D. 
• Immune parameters (day 11): In a MLDSTZ model of T1D, there was  
- no effect on splenic cell counts and cell viability obtained by aqueous/ethanol 
GKE;  
- no effect/trend of decrease in T cell proliferation obtained by aqueous/ethanol 
GKE;  
- a decrease in the percentage of T cells and T cell subpopulations obtained by 
aqueous/ethanol GKE  
- an increase in TNFα, IFNγ, and IL-6 levels with a decrease of IL-2 obtained in 
splenocytes of mice treated with aqueous GKE; an increase of IL-17A, IL-10, 
TNFα, and IL-6, a trend of increase in IFNγ, and a decrease of IL-2 obtained in 
splenocytes of mice treated with ethanol GKE. 
• Immune parameters (day 30): In a MLDSTZ model of T1D, there was  
- no effect on splenic cell counts and cell viability obtained by aqueous/ethanol 
GKE;  
- no effect on T cell proliferation obtained by aqueous/ethanol GKE  
- a decrease in the percentage of T cells and T cell subpopulations obtained by both 
GKE types 
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- an increase in IL-10, and a trend of increase in TNFα, and IL-6 levels with a trend 
of decrease in IL-2 obtained in splenocytes of mice treated with aqueous GKE; a 
trend of increase of TNFα, IFNγ and IL-6, with a trend of decrease in IL-2 
obtained in splenocytes of mice treated with ethanol GKE. 
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Chapter V: Discussion 
Effects of GKE Extracts on Glycemia, Body Weight and T1D Incidence  
In initial experiments, mice were treated with aqueous GKE in their drinking water, as 
this was the most physiologically relevant route to humans’ consumption of GK seeds. Contrary 
to the previous reports of GK-induced hypoglycemic effects (Adedara et al., 2015; Adaramoye 
2012; Ayepola et al., 2013; Farahna et al., 2017; Iwu et al., 1990; Tchieme et al., 2016), the 
aqueous GKE treatment did not lower glycemia in diabetic mice in our study. However, in 
previous studies glucose measurements were obtained on fasted animals, which we did not use, 
as fasting is known to stress the experimental mice (Jensen, Kiersgaard, Sørensen, & Mikkelsen, 
2013). To ensure that the STZ itself did not interfere with the potential effects of GKE on 
glycemia, the experimental group was formed in which STZ-free animals were treated by 
aqueous GKE; still, no hypoglycemic effects were observed in these mice.  
The dose of 100 mg/kg GKE was chosen as it was the most commonly used efficient 
dose in previous studies. The hypoglycemic effects were observed in both diabetic and not 
diabetic animals by using this dosage (Adaramoye 2012; Ayepola et al., 2013; Farahna et al., 
2017). Since no hypoglycemic effect was obtained by 100 mg/kg GKE, we assumed that a lower 
dose would not be efficient. In a 2017 study done by Farahna et al., diabetic rats treated with 
aqueous GKE at 50 mg/kg did exhibit a hypoglycemic effect, but it was not restored to control 
levels. A dose higher than 100 mg/kg was also not used because of the potential adverse health 
effects. A study done by Chinedu et al. described rats treated with aqueous GKE at 450 mg/kg 
and 900 mg/kg. Whereas hypoglycemic effects were achieved, an elevation of hepatic serum 
enzymes, indicating toxicity-related liver damage, was observed as well (Chinedu et al., 2013).  
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We also questioned whether differences in the experimental design, particularly freshness 
of GKE, treatment administration, and the extraction method influenced observed differences in 
glycemia results compared to previous studies. Since the Garcinia kola seeds were provided a 
year before the experimental execution, we wondered whether the freshness of the seeds 
impacted the presence of the active compound, kolaviron (KV). Thus, aqueous GKE samples  
were sent for LC-MS analysis, which confirmed the presence of four out of five flavonoids that 
constitute KV. Though our extracts did contain active flavonoid compounds, the fresh seeds 
were purchased, and a new experimental group of mice was treated with aqueous GKE prepared 
from these seeds. Again, a hypoglycemic effect was not observed.  
Another factor taken into consideration was the frequency of freshly prepared GKE-
enriched water, as in a few previous studies the GKE preparation was performed daily (Adedara 
et al., 2015; Farahna et al., 2017). Thus, a daily preparation and administration of GKE working 
solution was executed, instead of originally proposed every five days. Even this modification did 
not make a difference in observed glycemic levels of treated mice.  
Furthermore, in previous studies, the main method of GKE administration was oral 
gavage (Table 1). Whereas this method ensures precise dosage, it is not as physiologically 
relevant as the method we chose in mimicking human consumption. In addition, when animals 
are treated orally (drinking or eating), an interaction with mucosal surfaces in the mouth can lead 
to more efficient absorption and transport as well as  evasion of first pass metabolism, resulting 
in higher bioavaibility of the compound (Vandenberg, Welsons, vom Sall, Toutain, & Myers, 
2014).  
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Unlike previous work, the GKE treatment in this study began before induction of T1D, 
ensuring its effects on the pancreas and glycemia level before chemically-induced damage of 
beta cells. In diabetic mice treated with aqueous GKE, significant increase in body weight was 
observed, suggesting that GKE can restore the weight lost caused by the progression of T1D. 
This weight gain is congruent with the previously published data on rats chronically treated with 
KV for six weeks (Ayepola et al., 2013), three weeks (Adaramoye, 2012) and 30 days (Farahna 
et al., 2017). Interestingly, in non-diabetic STZ-free mice treated with GKE, although not 
significant, there was observed a trend of decrease in body weight, which was also previously 
seen in non-diabetic rats (Ayepola, et al., 2013).   
The extraction method we utilized (modified version of Ogunmoyole et al., 2012) used 
water as a solvent, whereas most of the previous studies used a method originally developed by 
Iwu (1984). This method involved more polar solvents, which yielded the active compound 
mixture (KV). Since no hypoglycemic effect was observed in aqueous GKE-treated mice, we 
wondered whether an ethanol-extracted GKE would do so. It was previously reported that an 
ethanolic extraction of GK fruits yielded more flavonoid content than an aqueous extraction, 
suggesting that an ethanol-based extraction would have more potent antidiabetic effects 
(Ogynmoyole et al., 2012). However, our results obtained using ethanol GKE did not confirm its 
hypoglycemic effect in diabetic or STZ-free mice. Hypoglycemic effects were previously 
observed in non-diabetic rats treated with KV at the same dose of 100 mg/kg (Ayepola et al., 
2013; Farahna et al., 2017; Iwu et al. 1990). In contrast, non-diabetic STZ-free mice treated with 
ethanol GKE have significantly higher glycemia levels compared to control mice.  
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To our best knowledge, this study is the first study to investigate the effects of GKE on 
T1D incidence. Treatment with either aqueous or ethanol GKE had no effect on diabetes 
incidence and prevalence. GKE of either extraction type did not delay T1D development, nor 
reduced the number of diabetic animals.  
Though no hypoglycemic or antidiabetic effects were seen in STZ-treated C57BL/6 mice, 
we questioned whether the STZ introduction, necessary to generate chemically-induced 
MLDSTZ model of T1D (Leiter & Schile, 2014), would interfere with the potential effects of 
GKE. Thus, later experiments were conducted on female NOD/LtJ mice, a strain that 
spontaneously develops T1D. (Leiter & Schile, 2014). Though there was no difference in 
glycemia when C57BL/6J mice were treated with ethanol GKE, we chose to treat NOD females 
with ethanol GKE, speculating about its higher potency (Ogynmoyole et al., 2012). The five-
month-long ethanol GKE treatment of NOD females did not affect either glycemia levels  or 
diabetes incidence. Based on the results of multiple experiments, performed with both aqueous 
and ethanol GKE it can be concluded that treatment with GKE does not reduce glycemia nor  
diabetes incidence in MLDSTZ and NOD models of T1D. 
The lack of glycemic effects may be related to how the active compounds within GKE 
are absorbed and metabolized.  The metabolism and absorption of flavonoids is not completely 
understood, and rates of both differ among the subclasses of flavonoids (Hollman, 2004). KV is a 
complex containing five flavonoids: GB-1, GB-2, kolaflavone, kolaflavonone, and binarigenin. 
The most active flavonoids in this complex, previously studied and found to exhibit 
hypoglycemic effects, are mainly GB-2, then GB-1 and kolaflavone (Adaramoye, 2012; Ayepola 
et al., 2013). The individual flavonoids are structurally similar; differences are observed 
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primarily within different side chains at the R3 and R4 position (Adedara et al. 2015; Ayepola et 
al. 2013).  
In both of our aqueous and ethanol GKE samples, that were analyzed via LC-MS 
(positive ion ESI), GB-1, GB-2, kolaflavonone, and binarigenin were present, whereas 
kolaflavone was not present in either extraction type. Interestingly, the (m/z) values for each 
flavonoid present in the GKE samples were consistently an additional two atomic mass units 
higher than the (m/z) values previously published by Ayepola et al. (2013). This consistency 
suggests that the two ketones present in each flavonoid were protonated. Despite the 
confirmation of four flavonoids in the GKE extracts used in this study, three of which are most 
attributed to hypoglycemic effect, a reduction of blood glucose levels was not observed in this 
study, regardless of the type of GKE extract.  
Effects of GKE Extracts on Immune Parameters  
To our best knowledge, this study was the first study to extensively investigate the effects 
of GKE on the immune system. Immune parameters, such as T cell proliferation, splenic cell 
counts and viability, T cell subtypes and their cytokine profiles were studied at two different time 
points, on day 11 and 30, during the development of T1D in MLDSTZ mice treated with aqueous 
and ethanol GKE. Overall, no reduction in splenic cell numbers and viability was observed, 
suggesting that GKE extracts did not exhibit toxic effects on the immune system. The reduction 
in percentages of T cells and T cell subpopulations, with a trend of decreased T cell proliferation 
were observed. The cytokine profiles suggested a Th1 pro-inflammatory shift, with a significant 
elevation of Th-1-type cytokine levels, especially on day 11. Day 11 was chosen, as a 
representative day in the second week after the initial STZ injection, which is a critical period in 
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the development of T1D in the MLDSTZ model.  T cells are the most active and mice are 
becoming diabetic in that period (Hobbs, 2011). Thus, the most prominent GKE-induced effects 
on T cell activity are expected to be observed during that period, with the lingering, declining 
effects on day 30 (Hobbs, 2011). Th-1-type cytokines were profoundly elevated at the beginning 
of disease development on day 11, whereas a non-significant trend in increase of Th1-cytokines 
remained on day 30, suggesting that a GKE-induced shift towards a pro-inflammatory response 
occurs early in T1D development. Even a significant increase of IL-10  was observed on day 30, 
indicating a compensatory increase of Th-2-type response. Interestingly, among both aqueous 
and ethanol GKE-treated mice, a decrease in IL-2 was observed. This finding supports the 
decreased proliferation index, as IL-2 is crucial for T cell activation and subsequent proliferation. 
However, IL-2 results do not corroborate  GKE-induced shift to the Th1 response. Due to the 
increase in the pro-inflammatory cytokines, it would be expected to see a parallel increase in T 
cell proliferative capacity.  
Based solely on immunophenotyping data, showing significant reduction in T cell 
population and T cell subtypes, one would expect to observe the signs of immunosuppression in 
GKE-treated mice, and a consequent prevention of T cell-mediated T1D. Though there are 
decreased relative and even absolute levels of T cells and Th/Tc subpopulations in GKE-treated 
mice, the profiling of their cytokines suggests GKE-induced skew towards pathogenic Th1-type 
response. Thus, it seems that GKE treatment, while decreasing T cells, makes them even more 
pathogenic, with a resulting unaltered T1D development.  
A possible mechanism of action, not elucidated in our study, would be that GKE 
promotes NFκB expression, a key transcription factor involved in the production of numerous 
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pro-inflammatory cytokines and other inflammatory markers. Another plausible speculation 
would be an interaction of GKE with the aryl hydrocarbon receptor (Ahr). The Ahr is responsible 
for binding environmental pollutants that are metabolized primarily through the upregulation of 
cytochrome p450 (Julliard, Fechner, & Mezrich, 2014). Once the receptor is activated, it can 
promote the differentiation of Th17 or Tregs. It is of general thought that exogenous ligands (i.e. 
environmental pollutants) promote Th17 differentiation, whereas endogenous ligands promote 
Tregs (Julliard et al., 2014). Although flavonoids are considered  as ligands for Ahr, which can 
act either agonistically or antagonistically (Amakura et al., 2008), the interaction of  GKE and 
the Ahr remains to be elucidated. While the effects of KV or GKE on T cells have never been 
studied before, results from Ayepola et al. (2013) showed that treatment with KV exhibited anti-
inflammatory properties in the lysate of rat liver through a reduction of IL-6 and TNFα levels. 
They proposed that KV suppresses NFκB expression (Ayepola et al., 2013) (Table 2). It is 
apparent that neither aqueous nor ethanol GKE exhibited anti-inflammatory effects in the 
MLDSTZ experimental model of T1D. However, GKE-induced shift towards a Th1 response, 
observed in our study, could be beneficial in other diseases, such as asthma or allergies in 
general, in which increased Th1 cytokines serve as a protective by decreasing pathogenic Th2 
response. In a study done by Liu, Li, Zhang, Zhang, and Yang, the effects of a citrus fruit 
flavonoid, tangeretin, were investigated on ovalbumin-induced asthma in BALB/c mice. It was 
found that tangeretin decreased IL-4, IL-5 and IL-13 levels, while increasing IFNγ (Liu et al., 
2017).  
Our in vitro exploration of GKE effects on T cell function, using low (2-100 ug/mL)- to 
extremely high-concentrations (250-1000 ug/mL) GKE, showed that aqueous extract had no 
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effect on Con A-induced T cell proliferation. Even a slight indication of a trend of 
immunosuppression was not observed. However, aqueous GKE, added in those high 
concentrations of 500 and 1000 ug/mL, induced a significant increase in three pro-inflammatory 
cytokines, TNFα, IL-17 and IL-6, whereas just the highest concentration of 1000 ug/mL GKE 
even increased the level of anti-inflammatory cytokine IL-4.  Previous work done by Abarikwu 
found that LPS-activated RAW264.7 murine macrophages treated with KV (~2.85 ug/mL to ~57 
ug/mL) decreased IL-6 production, while KV had no effect on TNFα (Abarikwu, 2014). In 
contrast, a study done by Onasanwo et al. found that LPS-activated BV2 microglia cells treated 
with KV (~2.85 ug/mL to ~11.4 ug/mL) exhibited a decrease in both IL-6 and TNFα (Onasanwo, 
Velagapudi, El-Bakoush, & Olajide, 2016). This study also investigated the effect of KV on 
NFκB and found that KV inhibited the activation and binding to target DNA (Onasanwo et al., 
2016). In our case, similar to the effects of GKE observed  on cytokines ex vivo, it is likely that 
GKE does not inhibit NFκB activation, but rather enhances it, explaining the increases in pro-
inflammatory cytokines.  
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Chapter VI: Conclusion 
In conclusion, this study does not support previously observed hypoglycemic and anti-
inflammatory effects of GKE. T1D incidence and prevalence, for the first time studied here, 
were not affected by either aqueous or ethanol GKE treatment. However, both types of GK 
extracts exhibited prominent effects on the immune system, inducing a reduction of T cells and T 
cell subpopulations, while skewing cytokine production towards pathogenic pro-inflammatory 
Th-1-type immune response. Whereas our data do not support GKE as a potential preventative 
treatment for T1D, they provide a strong evidence about GKE effects on T cells, suggesting 
GKE usage in other pathologies in which potentiation of pro-inflammatory Th-1 response would 
be beneficial.    
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Table 1. Summary of GKE’s effects on glycemia and body weight in previous studies. 
Reference Extraction 
method 
Experimental 
model 
GK dose, treatment 
regimen, and duration 
Administration 
method 
Effects on glycemia 
and body weight 
(bw) 
Iwu, et al 
(1990) 
Iwu soxhlet 
method (Iwu, 
1984) 
Rabbits 
 
Alloxan single dose 
150 mg/kg 
100 mg/kg  
 
One-time 
administration of KV 
IP injection Hypoglycemic effect  
Adaramoye, 
et al (2006) 
Iwu soxhlet 
method 
(Iwu, 1984) 
Male wistar rats 
 
STZ single dose 65 
mg/kg 
100 mg/kg 
Daily 
14 days 
KV, Fraction 1, 
Fraction 2, and Fraction 
3  
Oral gavage Hypoglycemic effect 
seen in KV, F1, F2 
but not F3 
Decreased body 
weight in diabetic 
rats (not F3) 
Adaramoye 
(2012) 
Iwu Soxhlet 
method (Iwu, 
1984) 
Male wistar rats 
 
STZ single dose 
35 mg/kg 
100 mg/kg 
Daily   
3 weeks  
Oral gavage Increased body 
weight in diabetic 
treated rats 
 
Hypoglycemic effect 
Ayepola, et 
al (2013) 
Iwu Soxhlet 
method (Iwu, 
1984) 
Male wistar rats 
 
STZ single dose 50 
mg/kg 
100 mg/kg  
 
5x a week  
 
6 weeks 
Gastric gavage Hypoglycemic effect  
 
Improved weight 
loss in diabetic rats 
 
 
Adedara, et 
al (2015) 
No extraction 
done 
 
Stock solution 
of GK 
(100mg/mL) 
was prepared 
fresh every 
other day with 
corn oil 
Male wistar rats 
 
STZ single dose 50 
mg/kg 
250 mg/kg 
 
14 days 
 
Orally* 
 
 
 
*not clearly 
defined 
No effect on bw 
 
Hypoglycemic effect 
Tchieme, et 
al (2016) 
Modified Iwu 
Soxhlet 
method (Iwu, 
1984) 
Male and female 
wistar rats 
 
Alloxan single dose 
200 mg/kg 
50 mg/kg  
 
KV, gb1, gb2, crude 
ethanol extract, 
garcinoic acid 
Oral gavage Overall 
hypoglycemic effect, 
best improvement in 
gb2 and crude extract 
treatment groups 
Farahna, et 
al. (2017) 
No extraction 
done 
 
Stock solution 
of GK (25 
mg/mL) was 
prepared daily 
in distilled 
water  
Male wistar rats 
 
STZ single dose 60 
mg/kg 
100 mg/kg  
Daily 
30 days 
Oral gavage Hypoglycemic effect 
Decreased bw in non 
diabetic rats 
increased bw in 
diabetic rats 
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Table 2. Summary of the effects of KV in vitro from previous studies. 
Reference Extraction 
method 
KV (particular 
fraction used), dose 
and treatment 
duration 
Cell and molecular 
targets studied  
Results  
Abarikwu 
(2013) 
Iwu Soxhlet 
method (Iwu, 
1984) 
5, 10, 15, 25, 50, 100 
uM  
~2.85 ug/mL to 57 
ug/mL 
24 hours 
 
 
mRNA expression and 
secretion of TNFα and 
IL-6 in RAW 264.7 
macrophages 
No effect on 
TNF-α 
Decreased IL-6  
 
Onasanwo 
et al. (2016) 
Iwu Soxhlet 
method (Iwu, 
1984) 
5-20 uM  
~2,85 ug/mL to 11.4 
ug/mL 
24 hours 
 
BV2 mouse microglia  
Cell viability 
TNFα and IL-6 
secretion 
No effect on cell 
viability 
Decreased 
TNFα and IL-6  
Muhammed 
et al (2017) 
Iwu Soxhlet 
method (Iwu, 
1984) 
5 ug/mL  
 48 hours 
Human PBMCs 
Mitotic index  
TLR2 and VEGFC 
mRNA expression 
Decreased 
mitotic index 
Down regulation 
of TLR2 and 
VEGFC  
Okoko & 
Ere 2012 
Not described **GB-1 and GB-2 
used 
2, 4, 8, 16 uM 
(~1.14 ug/mL to 9.12 
ug/mL) 
72 hours 
U937 macrophages 
Cell viability 
Cell activation 
TNF-α, IL-1, and IL-2 
secretion 
 
Increased cell 
viability 
 
Inhibition of 
activation 
Decreased TNF-
α, IL-1 and IL-2 
 
GB-2 more 
impactful than 
GB-1 
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